Healthcare Jun 28, 2022 10:08 AM (GMT+8) · EqualOcean
The Hong Kong Stock Exchange disclosed on June 27 that Yiming Angke biomedical technology (Shanghai) Co., Ltd. submitted the listing application to the main board of the Hong Kong stock exchange, with Morgan Stanley and CICC as the joint sponsors. As a research-oriented biotechnology company, Yiming oncology is committed to developing a new generation of tumor immunotherapy. As one of the few biotechnology companies in the world that can make systematic use of innate immunity and adaptive immunity, iminco stands out in the industry. It is understood that the company has established a comprehensive pipeline composed of more than ten candidate drugs targeting key innate and adaptive immune checkpoints, including five candidate drugs in the clinical stage (there are seven ongoing clinical research projects), three candidate drugs in the ind preparation stage and several candidate drugs in the discovery stage and preclinical stage.